New RSV prevention strategy for infants under study in bogotá
NCT ID NCT07279298
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study will check how well two RSV prevention methods work in real life: a vaccine given to pregnant women and an antibody shot given to newborns. Researchers will follow about 1,100 infants under 6 months old who are hospitalized with severe respiratory infections in Bogotá, Colombia. The goal is to see if these immunizations reduce severe RSV cases and hospital stays.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RSVpreF vaccine (Abrysvo) and nirsevimab (Beyfortus)
- What this could lead to
- If effective, these immunizations could prevent severe RSV infections in young infants, reducing hospitalizations and deaths.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less certain. Effectiveness may vary in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS, VIRAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Secretaria distrital de Salud
Bogotá, Colombia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nasal spray vaccine aims to shield children from RSV
- Inhaled interferon could be new weapon against severe RSV in young children
- New oral pill aims to fight RSV in adults
- New antiviral pill aims to shorten RSV symptoms in vulnerable adults
- New rapid test could spot flu and RSV in minutes at your local clinic
- Experimental 'Storm Stopper' therapy tested for COVID-19, flu, and RSV